Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
Adam R. Glassman, John A. Wells, Kristin Josic, Maureen G. Maguire, Andrew N. Antoszyk, Carl W. Baker, Wesley T. Beaulieu, Michael J. Elman, Lee M. Jampol, Jennifer K. Sun
Topics & Concepts
MedicineRanibizumabInterquartile rangeAfliberceptBevacizumabVisual acuityRandomizationHazard ratioConfidence intervalSurgeryRandomized controlled trialOphthalmologyInternal medicineChemotherapyRetinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeOcular Infections and Treatments